Salvianolic acid A ameliorates the integrity of blood-spinal cord barrier via miR-101/Cul3/Nrf2/HO-1 signaling pathway

Brain Res. 2017 Feb 15:1657:279-287. doi: 10.1016/j.brainres.2016.12.007. Epub 2016 Dec 21.

Abstract

Salvianolic acid A (Sal A), a bioactive compound isolated from the Chinese medicinal herb Danshen, is used for the prevention and treatment of cardiovascular diseases. However, the protective function of Sal A on preserving the role of blood-spinal cord barrier (BSCB) after spinal cord injury (SCI) is unclear. The present study investigated the effects and mechanisms of Sal A (2.5, 5, 10mg/kg, i.p.) on BSCB permeability at different time-points after compressive SCI in rats. Compared to the SCI group, treatment with Sal A decreased the content of the Evans blue in the spinal cord tissue at 24h post-SCI. The expression levels of tight junction proteins and HO-1 were remarkably increased, and that of p-caveolin-1 protein was greatly decreased after SCI Sal A. The effect of Sal A on the expression level of ZO-1, occluding, and p-caveolin-1 after SCI was blocked by the HO-1 inhibitor, zinc protoporphyrin IX (ZnPP). Also, Sal A inhibited the level of apoptosis-related proteins and improved the motor function until 21days after SCI. In addition, Sal A significantly increased the expression of microRNA-101 (miR-101) in the RBMECs under hypoxia. AntagomiR-101 markedly increased the RBMECs permeability and the expression of the Cul3 protein by targeting with 3'-UTR of its mRNA. The expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and HO-1 was significantly increased after agomiR-101 treatment. Therefore, Sal A could improve the recovery of neurological function after SCI, which could be correlated with the repair of BSCB integrity by the miR-101/Cul3/Nrf2/HO-1 signaling pathway.

Keywords: Blood-spinal cord barrier; Heme oxygenase-1; Salvianolic acid A; Spinal cord injury; Tight junction.

MeSH terms

  • Animals
  • Caffeic Acids / pharmacology*
  • Capillary Permeability / drug effects*
  • Capillary Permeability / physiology
  • Cardiovascular Agents / pharmacology*
  • Caveolin 1 / metabolism
  • Cullin Proteins / metabolism
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Heme Oxygenase (Decyclizing) / metabolism
  • Hypoxia / drug therapy
  • Hypoxia / metabolism
  • Lactates / pharmacology*
  • Male
  • MicroRNAs / metabolism
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • NF-E2-Related Factor 2 / metabolism
  • Neuroprotective Agents / pharmacology
  • Random Allocation
  • Rats, Sprague-Dawley
  • Spinal Cord / blood supply*
  • Spinal Cord / drug effects*
  • Spinal Cord / metabolism
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / metabolism
  • Tight Junctions / drug effects
  • Tight Junctions / metabolism
  • Zonula Occludens-1 Protein / metabolism

Substances

  • Caffeic Acids
  • Cardiovascular Agents
  • Cav1 protein, rat
  • Caveolin 1
  • Cul3 protein, rat
  • Cullin Proteins
  • Lactates
  • MIRN101 microRNA, rat
  • MicroRNAs
  • NF-E2-Related Factor 2
  • Neuroprotective Agents
  • Nfe2l2 protein, rat
  • Tjp1 protein, rat
  • Zonula Occludens-1 Protein
  • salvianolic acid A
  • Heme Oxygenase (Decyclizing)
  • Hmox1 protein, rat